Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
Open Access
- 12 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 556
Abstract
To date, there are no clinically effective neuroprotective or disease-modifying treatments that can halt Parkinson's disease (PD) progression. The current clinical approach focuses on symptomatic management. This failure may relate to the complex neurobiology underpinning the development of PD and the absence of true translational animal models. In addition, clinical diagnosis of PD relies on presentation of motor symptoms which occur when the neuropathology is already established. These multiple factors could contribute to the unsuccessful development of neuroprotective treatments for PD. Prodromal symptoms develop years prior to formal diagnosis and may provide an excellent tool for early diagnosis and better trial design. Patients with idiopathic rapid eye movement behavior disorder (iRBD) have the highest risk of developing PD and could represent an excellent group to include in neuroprotective trials for PD. In addition, repurposing drugs with excellent safety profiles is an appealing strategy to accelerate drug discovery. The anti-diabetic drug metformin has been shown to target diverse cellular pathways implicated in PD progression. Multiple studies have, additionally, observed the benefits of metformin to counteract other age-related diseases. The purpose of this viewpoint is to discuss metformin's neuroprotective potential by outlining relevant mechanisms of action and the selection of iRBD patients for future clinical trials in PD.Keywords
Funding Information
- King's College Hospital NHS Foundation Trust
This publication has 143 references indexed in Scilit:
- Exenatide and the treatment of patients with Parkinson’s diseaseJournal of Clinical Investigation, 2013
- Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine MetabolismCell, 2013
- The Role of Autophagy in Parkinson's DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Insulin resistance impairs nigrostriatal dopamine functionExperimental Neurology, 2011
- CREB: a multifaceted regulator of neuronal plasticity and protectionJournal of Neurochemistry, 2010
- PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s DiseaseScience Translational Medicine, 2010
- Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGFProceedings of the National Academy of Sciences, 2009
- Selective hyposmia in Parkinson disease: Association with hippocampal dopamine activityNeuroscience Letters, 2008
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998